The Philadelphia Business Journal named Wistar President and CEO Dr. Dario C. Altieri as one of the Most Admired CEOs of 2023, recognizing his steadfast commitment to community collaboration, excellence in science and innovation, and the transformative power of foundational research.

“I’ve had the privilege to lead The Wistar Institute for eight years now, and I continue to be inspired by all the people I have the opportunity to work with. To be recognized this way is truly a great personal and professional honor.”

Dr. Dario C. Altieri
PRESIDENT AND CHIEF EXECUTIVE OFFICER, THE WISTAR INSTITUTE
DIRECTOR, ELLEN AND RONALD CAPLAN CANCER CENTER
ROBERT AND PENNY FOX DISTINGUISHED PROFESSOR, IMMUNOLOGY, MICROENVIRONMENT AND METASTASIS PROGRAM
MARCH
An international team of researchers led by The Wistar Institute’s lead scientist on HIV-cure research publishes a review in the *Journal of Leukocyte Biology* supporting evidence that long COVID reflects tissue injuries to a patient’s system. Their review underscores the vulnerabilities of individuals with the disease and the immune consequences of their system responding to COVID.

Wistar researchers zero in on a promising plant-based compound called hopeaphenol, which targets HIV reservoirs that persist in people living with HIV despite the presence of anti-HIV therapy.

“*Our work will advance efforts to identify therapy strategies to avoid tissue injury leading to long COVID from that initial infection.*

Dr. Luis J. Montaner
HERBERT KEAN, M.D., FAMILY PROFESSOR; DIRECTOR OF THE HIV-1 IMMUNOPATHOGENESIS LABORATORY AND LEADER OF THE HIV RESEARCH PROGRAM WITHIN THE VACCINE & IMMUNOTHERAPY CENTER
IN 2023, Wistar scientists authored or co-authored 135 published journal articles.

APRIL
Wistar’s Dr. Luis J. Montaner joins local and international dignitaries in Vietnam’s Ho Chi Minh City to mark the start of the AMOHI Clinical Trial investigating the impact of medications for opioid use disorder on immune recovery in response to antiretroviral therapy. The launch is the culmination of two major grants from the National Institute on Drug Abuse.

MAY
Wistar researchers successfully engineer a linked molecule that enables a three-modality therapy to improve outcomes for melanoma. Their work connects a cytokine and an antibody — ordinarily administered separately — and then engineers a combination that is pro-inflammatory enough to fight cancer cells, but not so inflammatory as to cause complications or reduce survival outcomes.

JUNE
A new study by Wistar scientists published in *Nature Communications* shows that a type of brain cell called an astrocyte plays an important role in promoting brain metastasis by recruiting a specific subpopulation of immune cells. The team hopes to identify the best therapeutic window for treating and stopping this process.

JULY
Wistar researchers uncover how the p53 gene triggers immune function and, in turn, kills tumors — a critical discovery for the 4.4 million people who possess inherited mutations in p53 and are at increased risk of cancer. The collaborative work — which uses CRISPR engineering, the creation of tumor cell lines, and machine learning using bioinformatic approaches to create a gene signature — is published in *Cancer Discovery*.

AUGUST
Study results identifying a potential target for gastric cancers associated with Epstein-Barr Virus are published in the journal *mBio*.

“This work could not have happened in any other place except Wistar, where our environment is so collaborative and cutting edge.”

Dr. Maureen Murphy
DEPUTY DIRECTOR, ELLEN AND RONALD CAPLAN CANCER CENTER AND IRA BRIND PROFESSOR AND PROGRAM LEADER IN THE MOLECULAR & CELLULAR ONCOGENESIS PROGRAM
SEPTEMBER
Using immunosensitization — the process of guiding the immune system to the cancer — a Wistar team drastically reduces tumor growth to the point of completely wiping out triple-negative breast cancer in some experiments in preclinical models.

NOVEMBER
Scientists from Wistar’s Vaccine & Immunotherapy Center engineer novel monoclonal antibodies to activate the body’s immune system against hard-to-treat ovarian cancer. The collaborative work, published in Science Advances, uses a new target on “natural killer” cells known as Siglec-7, which may be a hoped-for key to engaging the immune system, shrinking tumors, and prolonging survival from ovarian cancer.

DECEMBER
Wistar scientists, under the direction of Dr. Noam Auslander, assistant professor in the Molecular & Cellular Oncogenesis Program, develop a new tool to help identify cancer-associated microbes by using machine learning technology.

JANUARY
Dr. Noam Auslander, assistant professor in the Molecular & Cellular Oncogenesis Program, is named a Michelson Prize laureate by The Michelson Medical Research Foundation and the Human Immunome Project. The award supports early-career investigators and their work advancing the immunology, vaccine, and immunotherapy field. Dr. Auslander’s lab develops machine learning approaches to detect microbes in cancer and immune diseases.
OCTOBER
Dr. Daniel Claiborne, Casper Wistar Fellow, is using two newly acquired grants, one from amfAR, The Foundation for AIDS Research, and another from The Campbell Foundation, to explore using supercharged CAR T immune cells as nontraditional HIV therapy. The Caspar Wistar Fellows Program prepares the next generation of scientific leaders for independence as principal investigators.

NOVEMBER
GSK awards The Wistar Institute a $100,000 grant toward the expansion of its Biomedical Technician Training Program, enabling it to reach even more students and working professionals.

DECEMBER
The American Lung Association presents a COVID-19 Respiratory Virus Research Award in the amount of $100,000 per year for up to two years to Wistar Associate Professor Dr. Mohamed Abdel-Mohsen for his lab’s research exploring a COVID connection to lung disease.

Two Wistar scientists receive grants totaling $250,000 from the WW. Smith Charitable Trust. The funds will allow Dr. Noam Auslander to assess how certain ancient viruses that are native to our genome can affect how cancer responds to drug treatments, while Dr. Ian Tietjen will investigate whether a certain African bark extract can be used to activate the “hidden” HIV viral reservoir and make the virus vulnerable to a treatment that would eliminate it entirely.

JANUARY
Drs. Luis J. Montaner and Mohamed Abdel-Mohsen continue their collaborative work on a project funded by a two-year Target Grant from amfAR, The Foundation for AIDS Research. The project explores genetically engineered “natural killer” cells as HIV therapy.

MARCH
Wistar celebrates a quarter century of community-based academic research collaboration with the Philadelphia Foundation in fighting health care inequities faced by vulnerable populations. An $80,000 grant from the Robert I. Jacobs Fund expands ongoing Wistar research into ways to prevent, treat, and ultimately cure HIV to include pilot studies on SARS-CoV-2 and monkeypox vaccination outcomes in those living with HIV, as well as a study of persons with a prior history of monkeypox infection.

JULY
An innovative National Cancer Institute-funded Wistar/Harvard collaboration brings together experts in epigenetics, metabolomics, and drug discovery to investigate the link between Epstein-Barr Virus and epithelial cancers and, ultimately, identify better and more selective therapeutic targets.

“The discovery could be a missing link in the ‘shock and kill’ approach to HIV treatment that has been a focus of research for the past several years.”
—Dr. Mohamed Abdel-Mohsen

ASSOCIATE PROFESSOR, VACCINE & IMMUNOTHERAPY CENTER

PHILA FOUND .ORG

“By working together across different modalities, there’s an opportunity for each of us to learn from the synergy and expertise of the other investigators.”
—Dr. Paul Lieberman
HILARY KOPROWSKI, M.D., ENDOWED PROFESSOR AND DIRECTOR OF THE CENTER FOR CHEMICAL BIOLOGY AND TRANSLATIONAL MEDICINE

A YEAR OF DISCOVERY ADVANCED BY GRANTS & AWARDS
MAY
Wistar scientists in Philadelphia continue to deepen a fruitful international collaboration with computational chemistry experts from the University of Buea Centre for Drug Discovery in Cameroon to identify plant-based medicinal compounds that may hold potential for treating HIV. In a collaboration that advances both research programs — and human health worldwide — Wistar exchanges knowledge in laboratory techniques and research infrastructure for advanced computer modeling expertise for screening therapeutic compounds found in African plants.

Biotech startups in the tri-state region get a boost from Wistar’s newly formed strategic collaboration with the Pennsylvania Biotechnology Center and the Baruch S. Blumberg Institute. The collaboration — designed to collectively support the seeding, launching, and maturation of life science startups — will feature a translational sciences seminar series.

JUNE
Wistar and the federally qualified health center Philadelphia FIGHT honor pediatric HIV researcher Dr. Deborah Persaud of the Johns Hopkins University School of Medicine at the 27th Annual Jonathan Lax Memorial Award Lecture, held in person and streamed to a global research and lay audience.

JULY
Wistar scientists team up with clinic and service providers at Philadelphia FIGHT and the BEAT-HIV Community Advisory Board in a new, more intentional community engagement model to achieve deeper insights and drive greater participation among the target community in HIV research.

“Joining forces to develop novel therapies against high-priority pathogens with future pandemic potential is an important step for global health.”
Dr. Luis J. Montaner
WISTAR VACCINE & IMMUNOTHERAPY CENTER

“This is a very unique, dynamic model because we are all working together. The scientists dream up the roadmap to implement cure research with collaborators. And then the community makes the dream our own. I don’t see how we can’t succeed.”
William B. Carter
CHAIRMAN, BEAT-HIV COMMUNITY ADVISORY BOARD

A YEAR OF DISCOVERY ADVANCED BY
COLLABORATIONS & PARTNERSHIPS

Wistar Science relies on the strength of our collaborations and partnerships to transform the discoveries and inventions of our researchers into new medicines and diagnostics. In 2023, we partnered with a range of institutions locally, nationally, and beyond to further our knowledge and bring meaningful solutions one step closer to those who need them.

WISTAR VACCINE & IMMUNOTHERAPY CENTER

“Joining forces to develop novel therapies against high-priority pathogens with future pandemic potential is an important step for global health.”
Dr. Luis J. Montaner
WISTAR VACCINE & IMMUNOTHERAPY CENTER

This is a very unique, dynamic model because we are all working together. The scientists dream up the roadmap to implement cure research with collaborators. And then the community makes the dream our own. I don’t see how we can’t succeed.”
William B. Carter
CHAIRMAN, BEAT-HIV COMMUNITY ADVISORY BOARD

A culture that fosters collaboration is key to Wistar’s success as a discovery engine. Resources to bolster those efforts are the transformative difference.

With funds raised from the Bold Science // Global Impact Campaign, Wistar will establish a Clinical Collaboration Fund to establish and nurture growing partnerships with local, national, and international clinicians and health systems, strengthening the bridge between Wistar research and patient treatment.

For more information on the Clinical Collaboration Fund and other Collaboration & Partnership Campaign priorities, visit boldscience.wistar.org or scan this QR code.

Clinical Collaboration Fund

WISTAR 2023: A YEAR OF DISCOVERY
Building a pipeline of talent has always been central to The Wistar Institute’s mission. Through the Hubert J.P. Schoemaker Education and Training Center, our goal is to advance a well-trained, sustainable life sciences workforce — comprising a diverse and inclusive talent pipeline — for the benefit of our region and beyond. In 2023, we continued to expand our offerings to even more individuals, from high school all the way through to working adults looking to expand their opportunities.

**February**

More than 175 postdoctoral, graduate, and undergraduate students from several academic institutions throughout the Philadelphia region exchange updates and generate ideas on peer-driven research at the inaugural Wistar Trainee Research Symposium.

“At Wistar, you feel part of something that is making breakthroughs. You feel like you can be someone who can make a discovery, too.”

Rickelle Wescott
 Research Experience for Undergraduates, Pre-Med Track, Hampton University

**June**

Fox 29 Good Day Philadelphia viewers are introduced to Wistar’s Biomedical Technician Training Program, which prepares the next generation of workers for positions in biomedical science labs. A recent graduate describes the training alongside world-renowned Wistar researchers as the “golden ticket” for full-time employment in the growing life sciences industry. Wistar is expanding the number and size of cohorts and training experiences thanks to recent National Science Foundation funding.

**July**

Wistar’s High School Program for Biomedical Research prepares next-gen scientists for exciting careers in life sciences research. Now in its 30th year, this innovative summer program offers a real-life dose of how science and medicine work at the cellular level in Wistar’s state-of-the-art biomedical research labs alongside the scientists who make discoveries happen.

**August**

Wistar kicks off its second Biomedical Technician Training Program cohort, preparing students with a high school equivalency for meaningful career opportunities in the burgeoning biotech workforce. The 24-week paid high-touch workforce training model offers graduates — many from disadvantaged communities — a direct path to full-time, career-ladder employment and is an essential step to meet the talent needs in the region’s rapidly growing cell and gene therapy sector.

**54 students from four Wistar summer Education & Training programs earn completion certificates during a combined recognition event featuring a keynote address, poster presentations, and reception.**

“We can tell students about these things, but when they actually get to contribute to the real research going on at Wistar, that’s when you see the spark.”

Dr. Kristy Shuda McGuire
Dean of Biomedical Studies
AUGUST

Wistar’s 12-week NSF-funded summer Research Experiences for Undergraduates Program fully immerses 16 students in biomedical science experiments under the guidance of a Wistar mentor scientist in one of the Institute’s 37 active labs. The program encourages STEM student innovators from underrepresented groups to pursue graduate education and eventual careers that will advance the life sciences in new directions.

NOVEMBER

Wistar trainees, researchers, staff, and family members don their sneakers, stretch their hamstrings, and take to the sidewalks of University City for the annual Wistar Champion Run for Research, raising more than $5,000 to support training, education, and the development of our next generation of biomedical researchers.

“...The collaborative nature of Wistar when I was a postdoc was so important to my development. I was thrilled to come back and help support other postdocs the way I was supported.”

Dr. Italo Tempera
ASSOCIATE DIRECTOR FOR CANCER RESEARCH CAREER ENHANCEMENT

A YEAR OF DISCOVERY ADVANCED BY EDUCATION & TRAINING

254 TOTAL PARTICIPANTS IN WISTAR’S EDUCATION & TRAINING PROGRAMS

59% WOMEN

18+ ACADEMIC AND INDUSTRY PARTNERS

140+ ADDITIONAL STUDENTS

Global Studies Program

Exchanges of science and scientific methods across institutions around the world enrich knowledge, foster a diverse pipeline of talent, and accelerate the discovery of new therapies and cures.

With funds raised from the Bold Science // Global Impact Campaign, The Wistar Institute will establish a Global Studies Program to elevate our presence on the global academic stage and pilot our highly successful training and workforce development initiatives abroad.

For more information on the plans for the Global Studies Program and other Education & Training Campaign priorities, visit boldscience.wistar.org or scan this QR code.

Global Studies Program

A YEAR OF DISCOVERY ADVANCED BY RECOGNITION

The talents of Wistar researchers and leadership are often recognized by peer organizations and outside associations for exceptional contributions to biomedical research and a commitment to the global science community. We’re also proud to honor other diverse collaborators and inspirational leaders in the field, who serve as models for our own researchers and aspiring future scientists.

APRIL

Internationally recognized tropical and emerging disease vaccinologist Dr. Maria Elena Bottazzi of Baylor College of Medicine in Texas keynotes Wistar’s Women & Science Program on Tropical Medicine Catalyzing Equity in the Vaccine Sciences. Dr. Bottazzi, who was a 2022 Nobel Peace Prize nominee and named among Forbes Latin American’s 100 Most Powerful Women in Central America, is co-creator of a patent-free, open science COVID-19 vaccine technology that led to development of vaccines suitable for global access.

JULY

Dr. Hildegund Ertl, professor in Wistar’s Vaccine & Immunotherapy Center, receives the Rosalind Franklin Society Award in Science, which recognizes outstanding peer-reviewed research by women and underrepresented minorities in STEM fields.
JULY

Dr. David Weiner, who directs one of the world’s most recognized research teams in the field of DNA vaccines and immunotherapies, is recognized with a 2023 Distinguished Research Award for Gene and Cell Therapy from MolecularCloud, a free platform for the biomolecular community. Dr. Weiner is the W.W. Smith Charitable Trust Distinguished Professor in Cancer Research, Immunology, Microenvironment and Metastasis Program.

SEPTEMBER

Wistar President and CEO Dr. Dario C. Altieri is honored by the Justinian Foundation and Society of Philadelphia for exemplifying the highest qualities of leadership and integrity. The Justinians, who espouse the advancement of professional, academic, civil, and cultural excellence, recognize Wistar’s role under Dr. Altieri’s leadership in preparing a diverse and inclusive talent pipeline in Philadelphia for the greater good of our global community.

NOVEMBER

Wistar presents its 2023 Helen Dean King Award, celebrating outstanding science achievement by women, to Dr. Cori Bargmann of The Rockefeller University. Dr. Bargmann is recognized for her work exploring the genetic and neural circuit mechanisms of behavior in pursuit of understanding how genes influence decisions. The award is named after a well-respected geneticist and member of Wistar’s research staff from 1908 to 1950, Dr. Helen Dean King — the first female scientist to work at Wistar.

DECEMBER

The Philadelphia Business Journal selects Dr. Dario Altieri, Wistar President and CEO, as one of Philadelphia’s Most Admired CEOs leaving a mark on Greater Philadelphia and beyond.

The Society for Melanoma Research (SMR) presents Dr. Meenhard Herlyn with the Founders Award to commemorate his work in creating an organization that has been integral to the advancement of melanoma research. Dr. Herlyn founded SMR in 2003 to bring together clinicians and researchers against melanoma.

MELANOMA WALK

$100,000 MILESTONE FOR TEAMS ELBO AND PATIO

Congratulations to Eleanor Armstrong (orange sweatshirt), Pat Dean (green shirt), and the entire Team Elbo and Team Patio crew on surpassing $100,000 lifetime raised in support of melanoma research at The Wistar Institute!

To learn more about the 8th Annual Melanoma Fundraising Walk that took place on October 15, 2023, and how you can raise funds in support of Wistar Science, scan the QR code or visit wistar.org/give-join/fundraising-wistar/
A YEAR OF DISCOVERY ADVANCED BY TEAMWORK

Our people are the heart of our work, from world-renowned researchers making new discoveries to expert administrative staff and exceptional Trustees who help advance Wistar’s mission.

JANUARY

Michael Criscuolo joins The Wistar Institute as vice president of Development. Criscuolo’s expertise in health care fundraising and knowledge of Philadelphia’s life sciences community will help secure philanthropic support to advance Wistar’s global leadership in the areas of cancer research and in the development of vaccines and immunotherapy.

MARCH

Legal and life sciences expert Squire Servance, founder and managing partner of Syridex Bio, joins the Wistar Board of Trustees, serving on the Audit, Business Development, and Scientific Advisory committees.

JULY

Wistar welcomes virology expert Dr. Alexander Price as a new assistant professor in the Gene Expression and Regulation Program of the Ellen and Ronald Caplan Cancer Center. In his new Price Lab at Wistar, Dr. Price will focus on how viruses regulate and exploit RNA transcription and processing.

AUGUST

Life sciences consultant and entrepreneur Joy Taylor is appointed Wistar trustee, offering critical vision and insight as Wistar continues to build a life science ecosystem centered on excellence, collaboration, education, and innovation.

SEPTEMBER

Computational biologist Dr. Avi Srivastava is recruited as an assistant professor in Wistar’s Gene Expression and Regulation Program. The Srivastava Lab brings expertise in advanced computational methods used to establish powerful predictive research tools in cancer biology.

OCTOBER

Dean Stoios joins Wistar as Chief Financial Officer. Stoios brings to the role more than 25 years of experience in strategic planning, financial management, and driving successful growth in the private and academic sectors.

DECEMBER

Wistar welcomes Dr. Aleister Saunders and Dr. Patrick Oates to its Board of Trustees. Dr. Saunders serves as Executive Vice Provost of the Office of Research & Innovation at Drexel University, and Dr. Oates is Senior Vice President of Business Development & Strategic Planning for EMSCO Scientific, Inc.

Dr. Filippo Veglia, a prior staff scientist at Wistar, is recruited to its Immunology, Microenvironment and Metastasis Program as an assistant professor. Dr. Veglia studies glioblastoma, the most lethal form of brain cancer, in hopes that he can uncover potential weaknesses that could be targeted for treatment.

Scientific Talent Fund

Medical breakthroughs begin in bright minds: the creative, courageous imaginations of our current and future research faculty, as well as our alumni who honed their skills at the Wistar Institute.

With funds raised from the Bold Science // Global Impact Campaign, Wistar will establish a Scientific Talent Fund to ensure that the organization remains highly competitive in its ability to attract, recruit, and retain world-class talent.

For more information on the plans for the Scientific Talent Fund and other Biomedical Research Campaign priorities, visit boldscience.wistar.org or scan this QR code.

“Wistar scientists are doing ambitious science, but the educational component and STEM equity is equally critical, and Wistar is leading the way training the next leaders in the life sciences space.”

Squire Servance WISTAR TRUSTEE

MEMBER NEWS

Dr. Maureen Murphy is named deputy director of Wistar’s NCI-designated Ellen and Ronald Caplan Cancer Center, a position in which she helps guide the center’s growth by expanding research initiatives and collaboration, education and training programs, and recruitment to fast-track innovative basic cancer research discoveries into future transformative drugs and therapies. Dr. Murphy also serves as program leader of Wistar’s Molecular & Cellular Oncogenesis Program, associate vice president for Faculty Affairs, and principal investigator of the Training Grant in Cancer Biology.
In 2023, Wistar added a number of new technology offerings that elevate our world-class scientists’ capacity to approach every research question with a laser focus on therapeutic potential. Among them are instruments that provide Wistar scientists with deeper insights for cell tissue phenotyping, cell-cell interactions, cellular processes and biomarker discovery; precision tools for preclinical modeling; next-generation fluorescent imaging; and powerful, high-resolution image construction.

NANOSTRING GEOMX DIGITAL SPATIAL PROFILER (DSP)*
A powerful tool for examining cellular interactions, tissue heterogeneity, pathogenicity, and response to therapy.

NANOSTRING COSMX SPATIAL MOLECULAR IMAGER (SMI)*
Allows researchers to see fresh/frozen samples at single-cell and subcellular resolution.

LEICA STELLARIS 8 3X T auSTED SYSTEM*
This brand-new confocal microscope brings the power of next-generation fluorescent imaging to Wistar, using state-of-the science imaging physics technology to achieve nonpareil resolution — down to about 30 nanometers — allowing scientists to see things as small as certain virus particles.

HAMAMATSU NANOZOOMER S60 SLIDE SCANNER SYSTEM
Combining powerful image construction technology with “set it and forget it” efficiency, this slide scanner renders dozens of high resolution 40X macro images at a time.

SMALL ANIMAL RADIATION RESEARCH PLATFORM (SARRP)
This precision radiation instrument for preclinical modeling allows scientists to administer exact doses of radiation to cells to study cancer, the immune system, and more.

In 2023, Wistar added a number of new technology offerings that elevate our world-class scientists’ capacity to approach every research question with a laser focus on therapeutic potential. Among them are instruments that provide Wistar scientists with deeper insights for cell tissue phenotyping, cell-cell interactions, cellular processes and biomarker discovery; precision tools for preclinical modeling; next-generation fluorescent imaging; and powerful, high-resolution image construction.

Technology Advancement Fund
With funds raised from the Bold Science // Global Impact Campaign, Wistar will establish a Technology Advancement Fund to continue to equip researchers at The Wistar Institute with the tools and resources necessary to drive innovation, accelerate scientific breakthroughs, and improve human health.

For more information on the Technology Advancement Fund and other Biomedical Research Campaign priorities, visit boldscience.wistar.org or scan this QR code.

* Made possible with a $2M Bold Science // Global Impact Campaign contribution from The Horace W. Goldsmith Foundation, in addition to funding from the Estate of Robert A. Fox.
Wistar’s independent nonprofit status creates a platform for our researchers to do original thinking and breakthrough research while also providing a community of collaboration not often found in larger medical and academic institutions. It is through the incredible generosity of our donors that we are able to expand and accelerate our progress on groundbreaking research programs to solve some of the greatest global public health challenges of our time.

Wistar extends our deepest admiration and appreciation for the below individuals, foundations, and corporations, whose lifetime support of the Institute totaled $1,000,000 or more at the conclusion of 2023.

**A YEAR OF DISCOVERY ADVANCED BY GENEROUS SUPPORT**

$25 MILLION+
Anonymous

$10 MILLION+
Ellen and Ronald Caplan
Penny and Robert* Fox
Bill & Melinda Gates Foundation
The Pew Charitable Trusts
Wellcome Trust

$5 MILLION+
Anonymous
Dr. Miriam & Sheldon G. Adelson Medical Research Foundation
The G. Harold & Leila Y. Mathers Charitable Foundation
W.W. Smith Charitable Trust

$1 MILLION+
Anonymous
American Cancer Society
amfAR
Mr. and Mrs. Douglas S. Briggs
Ira Brind and Stacey Spector
CEPI
Mrs. Eleanor Davis
Dr. Susan Dillon and Dr. William Wong
The Ellison Medical Foundation
Stan* and Arlene Ginsburg Family Foundation
Joseph and Jane Goldblum
The Horace W. Goldsmith Foundation
Ruth and Richard Horowitz
Innisfree
Herbert Kean, M.D. and The Honorable Joyce S. Kean

“Wistar is a place where we have an opportunity to make a difference for all mankind.”
Ellen and Ronald Caplan

*Deceased
The Wistar Institute’s 1892 Legacy Society was established to honor and recognize individuals who are thoughtfully providing for the future of Wistar through a Legacy Gift.

We deeply appreciate the commitment to the enduring efforts of Wistar made by the following living individuals who have included Wistar in their long-term financial or estate plans. In recognition of their long-lasting impact, we proudly affirm that they are members of the 1892 Legacy Society.

Already included Wistar in your estate plan?

Let us know so we can immediately welcome you as a member of the 1892 Legacy Society and recognize you today for your generosity. To learn more contact Brittany McCrimmon, Director of Development, at 215.495.6856 or email at bmccrimmon@wistar.org

wistar.plannedgiving.org

Thank You, Legacy Society Members!

Anonymous
Francis X. Bresnan
Ira Brind
June H. Chern
Dr. Matthew J. Cohen
Lisa Dykstra
Dr. Kendra B. Eager
Ms. Joan M. Farkas and
Mr. Bruce T. Downs
Mrs. Inez Flicker
Bruce A. and
Gale S. Gillespie
Mr. and Mrs. Stanley* Ginsburg
Dr. Alfred E. Goldman
Mr. and Mrs.
Bruce A. Goodman
Joseph Grussemyer
Mr. Saul Janson
Dr. and Mrs.
Russel E. Kaufman
Herbert Kean, M.D.
and The Honorable
Joyce S. Kean
Mr. and Mrs.
Joseph D. Kestenbaum
Ms. Deborah Komins
Mrs. Diane M. Lafferty
Glorita M. Maida*
Mr. and Mrs.
Kurt L. Meyer
Ken Nimblett
Ms. Rosetta Perno
Mr. and Mrs.
Timothy P. Pesce
Dr. Harry Rosenthal
Mrs. Anne
Faulkner Schoemaker
Emily Brown Shields
Mr. James B. Wistar

*Passed away in 2023

Thank you to our 2023 President’s Society members!

The “What?”
The Wistar Institute’s President’s Society is home to Wistar supporters who provide an essential source of funding for Wistar through their annual giving.

The “How?”
President’s Society memberships are granted to those with cumulative giving of $1,000 or more to The Wistar Institute within a calendar year.

The “Why?”
Basic Science is where breakthroughs begin. It is the origin of all vaccines, drugs, trials, therapies, and cures. It is the first step in transforming health and saving lives.

The “Wow!”
PRESIDENT’S SOCIETY MEMBER GIVING:
• sustains our ongoing, groundbreaking research and funds novel science projects at their earliest stages;
• supports our education initiatives from high school to postdoctoral work as well as workforce development programs, funneling diverse talent into well-paying jobs in the life sciences;
• helps us attract and retain top talent;
• funds new technology and equipment;
• bridges unanticipated gaps in grant funding; and
• enables Wistar to pivot quickly to respond to emerging needs like COVID-19; and so much more!

“I’m really grateful for my doctors and everything that got me to this point, but my cancer treatment actually started with the research at places like The Wistar Institute and I wanted to be a part of the beginning.”

Elizabeth Pesce
CANCER SURVIVOR AND WISTAR PRESIDENT’S SOCIETY MEMBER

Join this exclusive network of leaders with a gift to The Wistar Institute today:
wistar.org/give-join

Join the 1892 Legacy Society
You decide how you give.
Uncover the giving option that works best for your goals.

There are several ways to establish a Legacy Gift, including bequests, beneficiary designations, and various financial vehicles that provide either upfront or deferred support to Wistar.

These gifts can often also enable individuals to make a contribution to Wistar at a level that may not have been possible at an earlier stage of life or during their lifetime. Such gifts also offer certain tax benefits and can provide advantages such as a lifetime income to the donor or others.

Most importantly, all Legacy Gifts give our supporters the opportunity to achieve their philanthropic goals in a way that is both meaningful and attainable for them and their families.

We are glad to assist you in determining a Legacy Gift that will best suit your needs and have a lasting impact on the future of Wistar.
Wistar’s global reputation and impact reflect a unique combination of strengths: a nimble organization that values collaboration above competition, where impact prevails over bureaucracy.

A once-in-a-century pandemic has shown the world that scientific freedom, agility, and cooperation can rechart the course of human health when given ample capacity and investment. Our bold action now will propel long-lasting improvements to health and the life sciences through our biomedical research and educational initiatives.

Rooted in The Wistar Institute’s strategic plan, the Bold Science // Global Impact Campaign for Wistar will enable a transformative investment to bolster and propel key new initiatives across our three foundational pillars.

**BIOMEDICAL RESEARCH**

Following the science and cultivating curiosity to find answers and identify solutions for today’s most pressing scientific problems; our bold objectives include:

- Expand and ensure evergreen scientific talent.
- Ensure access to the most advanced technologies and research capabilities.
- Sustain and advance our focus on cancer, immunology and infectious diseases to develop the medicines of tomorrow, new life-saving vaccines and next-generation immunotherapeutics.

**EDUCATION & TRAINING**

Building a pipeline of talent through outreach, mentorship, and an investment in bright young minds; our bold objectives include:

- Secure sustainable funding for Wistar’s core education and workforce development programs.
- Expand the continuum of Wistar educational programs to create a diverse, inclusive life sciences talent pipeline.

**COLLABORATION**

Taking a team science approach—locally and globally—that advances basic research discoveries to lifesaving clinical therapies; our bold objectives include:

- Broaden Wistar connections to clinicians, patients and specimens.
- Leverage internal award mechanisms and expand the Wistar Science Discovery Fund endowment to advance and accelerate Wistar discoveries into clinical trials with external collaborators.
With more than $52 million raised to date, the Bold Science // Global Impact Campaign for Wistar is already having a transformational impact on the Institute. Here are some of the bold achievements made possible through Campaign support thus far.

**BOLD ACHIEVEMENTS**

- Five newly-created, endowed professorships in Cancer Research, Vaccines & Immunology, and HIV & Infectious Diseases
- Expansion of core educational cohorts, including the Biomedical Technician Training program, high school program, and college programs
- Foundation of a new Center for Advanced Therapeutics devoted to the custom design and development of tailored next-generation immunotherapy-based medicines
- Expansion of Cancer Center funding
- Establishment of new Principal Investigator Accelerator Awards to fund innovative, early-stage research projects
- Funding of a Pandemic Preparedness Program for emerging threats
- Launch of new International Postdoctoral Fellowship
- Equipment acquisitions for the state-of-the-art Training Laboratory

**BOLD OPPORTUNITIES**

We invite you to be among the visionary donors to the Bold Science // Global Impact Campaign for Wistar. Contributions will fuel our remaining Campaign priorities, including:

- Scientific Talent Fund
- Caspar Wistar Fellowship renewal
- Technology Advancement Fund
- Endowed Dean of Biomedical Studies
- Education endowments
- Global Studies Program
- Biomedical Technician Training Program expansion
- High school program expansion
- International Postdoctoral Fellowship
- Clinical Collaboration Fund
- Wistar Science Discovery Fund endowment expansion

“With Wistar Science we can fulfill both a dream and a promise. Where discovery solves big problems, knowledge improves lives and innovation creates new futures — this is our moment.”

Dr. Dario C. Altieri

**BOLD IDEAS CHANGE LIVES. BOLD SUPPORT MAKES IT POSSIBLE.**
The Wistar Institute is the nation's first nonprofit biomedical research organization. And since its earliest days, philanthropy has played a key role in advancing Wistar Science and its breakthrough discoveries. If you want to learn more about how you can support Wistar Science, visit wistar.org/give-join. The Wistar Institute is a 501(c)(3), tax ID# 23-6454596, and all gifts are tax deductible to the full extent allowed by law.

The Wistar Institute is an equal opportunity/affirmative action employer. It is the policy of the Institute to provide equal employment opportunities to all individuals regardless of race, citizenship, ethnicity, color, creed, religion, marital status, national origin, ancestry, sex, age, veteran status, mental or physical disability (including HIV and AIDS), pregnancy, caregiver status, domestic or sexual violence victim status, sexual orientation, gender identity and expression, or on the basis of genetic information, or any other characteristic protected by federal, state, or local law, with respect to all terms and conditions of employment. To comply with applicable laws ensuring equal employment opportunities, the Institute will attempt to make reasonable accommodations as required by law. Issues subject to reasonable accommodation may include religious belief or practice, gender identity, pregnancy or disability as required by law. For further information on accommodation of disabilities see the Americans with Disability Act (ADA) Policy. To contact the editor, email comm-marketing@wistar.org

© 2024 The Wistar Institute
Produced by The Wistar Institute Communications and Marketing Department
Designed by D.A. Perzel Creative
For additional copies or further information please contact Michele Schiavoni, ICSR, APR, MS, Vice President of Communications and Marketing, at mschiavoni@wistar.org